WO2025098503 - CEREBLON E3 UBIQUITIN LIGASE INHIBITOR
National phase entry is expected:
Publication Number
WO/2025/098503
Publication Date
15.05.2025
International Application No.
PCT/CN2024/131100
International Filing Date
08.11.2024
Title **
[English]
CEREBLON E3 UBIQUITIN LIGASE INHIBITOR
[French]
INHIBITEUR DE L'UBIQUITINE LIGASE E3 CÉRÉBLON
[Chinese]
小脑蛋白E3泛素连接酶抑制剂
Applicants **
GAN & LEE PHARMACEUTICALS CO., LTD.
Inventors
XU, Fuming
CHEN, Wenmin
ZHOU, Guan
XUE, Wei
DING, Yongzheng
LIU, Xiaobing
LI, Xiaoguang
Priority Data
202311479565.8
08.11.2023
CN
202311804797.6
26.12.2023
CN
202411250508.7
06.09.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3375 | |
| EPO | Filing, Examination, Granting | 23547 | |
| Japan | Filing, Examination, Granting | 2616 | |
| South Korea | Filing, Examination, Granting | 3199 | |
| USA | Filing, Examination, Granting | 7640 |
Total:
40,377
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to a new human cereblon (CRBN) E3 ubiquitin ligase inhibitor, which can be used for preparing PROTAC molecules. The CRBN E3 ubiquitin ligase inhibitor and the PROTAC molecules can be used for treating cancer and other diseases.[French]
La présente invention concerne un nouvel inhibiteur de l'ubiquitine ligase E3 céréblon (CRBN) humaine, qui peut être utilisé pour préparer des molécules PROTAC. L'inhibiteur de l'ubiquitine ligase E3 CRBN et les molécules PROTAC peuvent être utilisés pour traiter le cancer et d'autres maladies.[Chinese]
本发明涉及一种新的人小脑蛋白(CRBN)E3泛素连接酶抑制剂，其可用于制备PROTAC分子。CRBN E3泛素连接酶抑制剂和PROTAC分子可用于治疗癌症和其他疾病。